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Abstract	  	  
The	  human	  body	  is	  composed	  of	  trillions	  of	  cells,	  which	  are	  the	  fundamental	  units	  of	  
life.	  Understanding	  cell-­‐cell	  communication	  is	  essential	  in	  developing	  effective	  therapies	  for	  a	  
variety	  of	  diseases,	  including	  cancer.	  Current	  experimental	  approaches,	  such	  as	  ligands	  
presented	  in	  solution,	  lack	  the	  ability	  to	  describe	  cell-­‐cell	  communication	  because	  they	  do	  not	  
accurately	  mimic	  ligand	  immobilization	  nor	  do	  they	  make	  it	  possible	  to	  examine	  the	  effects	  of	  
ligand	  biophysical	  properties	  such	  as	  quantity	  or	  spatial	  arrangement.	  In	  order	  to	  better	  mimic	  
ligand-­‐receptor	  interactions	  during	  cell-­‐cell	  communication,	  a	  novel	  nanotechnological	  device	  
recently	  developed	  in	  the	  Nanoengineering	  Biodesign	  Laboratory.	  This	  device,	  called	  a	  Ligand	  
Presentation	  Platform,	  is	  a	  DNA	  origami	  engineered	  structure	  that	  enables	  precise	  control	  over	  
quantity	  and	  spatial	  arrangement	  of	  ligands	  presented	  to	  a	  cell	  surface.	  Precise	  structure	  
folding	  and	  ligand	  attachment	  was	  confirmed	  using	  gel	  electrophoresis	  and	  transmission	  
electron	  microscopy.	  Functional	  response	  was	  examined	  by	  adding	  nanostructures	  loaded	  with	  
anti-­‐CD40	  antibody	  to	  B	  cells	  transfected	  with	  Cignal	  GFP-­‐NF-­‐κB	  reporter	  construct.	  A	  
significant	  functional	  response	  up	  to	  4-­‐fold	  higher	  than	  relevant	  controls	  was	  observed	  via	  
single	  cell	  epifluorescence.	  These	  results	  demonstrate	  that	  the	  Ligand	  Presentation	  Platform	  
can	  induce	  a	  cellular	  functional	  response,	  making	  it	  possible	  to	  use	  the	  nanostructure	  to	  
examine	  the	  influence	  of	  spatial	  arrangement	  and	  quantity	  to	  provide	  detailed	  mechanistic	  
insight	  that	  can	  ultimately	  be	  utilized	  to	  design	  molecular	  therapeutics	  that	  target	  growth	  and	  
survival	  signaling	  networks	  in	  cancer	  cells.	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  GFP-­‐NF-­‐κB	  was	  measured	  on	  individual	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  
intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  condition.	  Images	  and	  data	  
represent	  two	  experiments. .............................................................................................................. 30	  
Figure	  20:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  B	  cells.	  Functionalized	  LPP12-­‐5T	  
(right)	  with	  controls	  (no	  stimulus,	  LPP	  with	  streptavidin,	  and	  LPP	  with	  isotype	  control	  antibody.)	  The	  
level	  of	  GFP-­‐NF-­‐κB	  was	  measured	  on	  individual	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  
intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  condition.	  Images	  and	  data	  
represent	  two	  experiments. .............................................................................................................. 31	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Figure	  21:	  Fluorescent	  microcopy	  to	  measure	  concentration	  dependence	  in	  B	  cells.	  Anti-­‐CD40	  
functionalized	  LPP1-­‐5T	  showed	  a	  concentration	  dependent	  change	  in	  signal	  induction.	  The	  level	  of	  
GFP-­‐NF-­‐κB	  was	  measured	  on	  at	  least	  40	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  
intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  condition.	  Images	  and	  data	  
represent	  one	  experiment................................................................................................................. 32	  
Figure	  22:	  Fluorescent	  microscopy	  to	  measure	  inhibition	  of	  signal	  in	  B	  cells.	  anti-­‐CD40	  functionalized	  
LPP2-­‐5T	  showed	  an	  ability	  to	  be	  inhibited	  by	  Bay-­‐11-­‐7082. ............................................................. 33	  
Figure	  23:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  T	  cells.	  Soluble	  anti-­‐CD3-­‐biotin	  was	  
added	  to	  T	  cells	  at	  60	  seconds.	  The	  level	  of	  intracellular	  calcium	  was	  measured	  on	  at	  least	  150	  cells	  
per	  condition	  and	  the	  data	  is	  presented	  as	  the	  intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  
hours	  for	  each	  condition.	  Data	  represents	  one	  experiment. ............................................................ 34	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Chapter	  1:	  Introduction	  
1.1	  Cancer	  and	  its	  Prevalence	  
The	  human	  body	  is	  composed	  of	  trillions	  of	  cells,	  which	  are	  the	  fundamental	  units	  of	  
life.	  Under	  normal	  circumstances,	  healthy	  cells	  systematically	  grow,	  differentiate,	  replicate,	  and	  
undergo	  apoptosis,	  or	  programmed	  cell	  death.	  This	  programmed	  death	  is	  a	  critical	  to	  maintain	  
healthy	  populations	  of	  cells.	  Occasionally,	  cells	  mutate	  or	  become	  damaged	  and	  rather	  than	  
undergoing	  apoptosis	  at	  an	  appropriate	  time,	  they	  become	  immortalized,	  begin	  to	  replicate	  
uncontrollably,	  invade	  surrounding	  tissues,	  and	  ultimately	  interfere	  with	  normal	  organ	  system	  
function,	  often	  leading	  to	  death.	  This	  disease	  phenotype	  is	  known	  as	  cancer.	  	  
Approximately	  14	  million	  people	  annually	  are	  diagnosed	  with	  cancer	  worldwide	  and	  
approximately	  8	  million	  of	  these	  people	  will	  die	  of	  cancer1.	  In	  the	  US	  alone,	  a	  projected	  1.6	  
million	  people	  will	  be	  diagnosed	  with	  cancer	  in	  2014	  and	  one	  in	  three	  diagnosed,	  or	  
approximately	  580	  thousand	  Americans	  will	  die	  of	  this	  disease2.	  	  
1.2	  Cancer	  Therapies	  and	  Relevance	  of	  Ligand-­Receptor	  Interactions	  	  
Major	  classes	  of	  cancer	  therapies	  include	  chemotherapy,	  radiotherapy,	  immunotherapy,	  
and	  surgery.	  Ideally,	  these	  therapies	  would	  kill	  or	  remove	  cancer	  cells	  without	  harming	  healthy	  
cells.	  However,	  since	  cancer	  cells	  are	  derived	  from	  healthy	  cells,	  differentiating	  between	  them	  
is	  an	  intricate	  and	  difficult	  task.	  	  
Some	  therapies	  interfere	  with	  the	  function	  of	  a	  specific	  molecular	  target,	  such	  as	  a	  
mutant	  kinase	  or	  extracellular	  protein,	  that	  exists	  on	  cancer	  cells	  at	  a	  higher	  rate	  than	  on	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healthy	  cells.	  This	  target,	  usually	  a	  protein,	  is	  often	  critical	  in	  cell	  progression	  such	  that	  
interfering	  with	  its	  function	  either	  halts	  cellular	  growth	  or	  destroys	  immortalized	  cells3.	  	  
In	  order	  to	  develop	  the	  next	  generation	  of	  effective	  targeted	  therapies,	  molecular	  
mechanisms	  that	  play	  a	  role	  in	  growth	  and	  survival	  must	  be	  well	  understood.	  	  Molecular	  
mechanisms	  are	  often	  initiated	  by	  cell-­‐to-­‐cell	  contact	  in	  the	  form	  of	  a	  biochemical	  signal	  passed	  
along	  by	  specific	  molecular	  interactions.	  A	  molecule,	  or	  ligand,	  on	  one	  cell	  engages	  a	  receptor	  
on	  another	  cell.	  This	  molecular	  binding	  event	  initiates	  a	  chain	  of	  events	  that	  propagates	  a	  signal	  
to	  ultimately	  execute	  a	  cellular	  response,	  such	  as	  growth	  or	  survival4.	  Understanding	  ligand-­‐
receptor	  interactions	  and	  the	  molecular	  mechanisms	  that	  these	  interactions	  govern	  allows	  for	  
therapies	  to	  be	  developed	  to	  attack	  the	  growth	  and	  survival	  of	  cancer	  cells	  such	  that	  therapies	  
that	  more	  effectively	  attack	  cancer	  can	  be	  developed.	  	  
1.3	  Current	  Method	  to	  Studying	  Ligand-­Receptor	  Interactions	  
The	  surface	  of	  cells	  possesses	  a	  variety	  of	  ligands	  and	  receptors	  that	  send	  and	  receive	  
numerous	  signals.	  Due	  to	  the	  complexity	  of	  ligand-­‐receptor	  interactions	  that	  coordinate	  
communication,	  studying	  and	  understanding	  their	  mechanisms	  can	  be	  quite	  arduous.	  The	  
current	  well-­‐defined	  experimental	  approach	  to	  study	  these	  interactions	  includes	  presenting	  
soluble	  ligands	  to	  cells	  and	  subsequently	  quantifying	  the	  functional	  cellular	  phenotypic	  and	  
proximal	  molecular	  responses.	  However,	  physiologically,	  a	  cell	  is	  often	  presented	  ligands	  that	  
are	  attached	  to	  a	  surface	  (e.g.	  cell	  membrane	  or	  tissue.)	  Therefore,	  soluble	  ligands	  often	  do	  not	  
mimic	  a	  natural	  cell-­‐cell	  interaction.	  	  While	  a	  ligand	  in	  solution	  can	  interact	  with	  cell	  surface	  
receptors	  in	  a	  variety	  of	  conformations	  and	  orientations,	  a	  surface	  ligand,	  for	  example	  a	  cell	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membrane,	  would	  engage	  a	  receptor	  in	  a	  more	  immobilized	  manner	  with	  physical	  support.	  The	  
goal	  of	  this	  work	  is	  to	  test	  a	  more	  representative	  method	  of	  studying	  cell-­‐signaling	  that	  includes	  
the	  ability	  to	  properly	  immobilize	  the	  ligand	  and	  examine	  the	  influence	  of	  effects	  such	  as	  ligand	  
spatial	  arrangement	  and	  ligand	  force	  or	  range	  of	  motion.	  	  
1.4	  Introduction	  to	  DNA	  Origami	  
	   DNA	  (Deoxyribose	  nucleic	  acid)	  is	  composed	  of	  nitrogenous	  bases,	  five-­‐carbon	  sugars,	  
and	  phosphate	  groups.	  While	  DNA	  is	  well	  known	  for	  encoding	  biological	  information	  and	  
forensic	  applications,	  intrinsic	  properties	  have	  allowed	  for	  the	  foundation	  of	  an	  entirely	  new	  
field	  of	  bionanotechnology,	  structural	  DNA	  nanotechnology,	  where	  the	  assembly	  properties	  of	  
DNA	  are	  exploited	  to	  construct	  objects	  with	  complex	  designed	  geometries.	  	  	   	  
The	  molecular	  structure	  of	  DNA,	  as	  shown	  below	  in	  Figure	  1	  and	  Figure	  2,	  is	  a	  twisted	  
ladder	  shape	  known	  as	  a	  double	  helix	  where	  the	  rungs	  of	  the	  ladder	  are	  formed	  by	  nucleotide	  
bases,	  adenine	  (A),	  thymine	  (T),	  cytosine	  (C),	  and	  guanine	  (G),	  and	  the	  legs	  of	  the	  ladder	  are	  
formed	  by	  the	  sugar-­‐phosphate	  backbone.	  In	  addition,	  the	  assembly	  of	  the	  double	  helix	  is	  
facilitated	  by	  hydrogen	  bonding	  in	  a	  manner	  such	  that	  the	  backbones	  of	  each	  strand	  run	  anti-­‐
parallel.	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Figure	  1:	  DNA	  Double	  Helix.	  	  DNA	  is	  a	  double	  helix,	  composed	  of	  antiparallel	  sugar-­‐phosphate	  backbones	  joined	  by	  four	  
nucleotides,	  depicted	  on	  the	  left.	  These	  nucleotides	  self-­‐assemble	  such	  that	  A	  binds	  to	  T	  and	  C	  binds	  to	  G	  via	  hydrogen	  
bonding.	  This	  self-­‐assembly	  property	  is	  important	  in	  the	  foundation	  of	  DNA	  Origami.5	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Figure	  2:	  The	  structure	  of	  DNA’s	  double	  helix	  is	  understood	  so	  precisely,	  that	  its	  dimensions	  are	  well-­‐defined	  on	  the	  
nanoscale.	  This	  structural	  property	  is	  important	  in	  the	  foundation	  of	  DNA	  Origami.6	  
	  
The	  design	  and	  fabrication	  of	  DNA	  nanostructures	  exploits	  the	  well-­‐understood	  
assembly	  properties	  of	  nucleic	  acids	  to	  design	  two	  and	  three-­‐dimensional	  nanoscale	  structures.	  	  
The	  field	  of	  DNA	  nanotechnology	  was	  founded	  with	  Ned	  Seeman’s	  work	  on	  nucleic	  acid	  
junctions	  and	  lattices	  in	  the	  early	  1980’s7	  and	  his	  subsequent	  synthesis	  of	  a	  DNA	  molecule	  with	  
cube	  connectivity	  in	  the	  early	  1990’s8.	  	  Since	  then,	  cumulative	  DNA	  nanotechnology	  related	  
citations	  have	  been	  published	  at	  an	  exponential	  rate	  and	  a	  variety	  of	  shapes	  and	  functions	  have	  
been	  proposed,	  as	  reviewed	  in	  “The	  enabled	  state	  of	  DNA	  nanotechnology.”9	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DNA	  origami	  is	  created	  by	  adding	  many	  30-­‐50	  base	  single	  stranded	  DNA	  (ssDNA)	  
oligomers	  to	  a	  long	  (~7000-­‐8000	  bases)	  circular	  ssDNA	  “scaffold”	  with	  a	  known	  sequence,	  such	  
that	  the	  oligomers	  bind	  to	  the	  scaffold	  in	  a	  piece-­‐wise	  manner	  to	  create	  a	  compact,	  high	  
precision	  geometry	  as	  described	  in	  Figure	  3.	  The	  scaffold	  is	  typically	  derived	  from	  the	  single-­‐
stranded	  genome	  of	  the	  M13MP18	  bacteriophage.	  The	  sample	  is	  initially	  heated	  to	  melt	  all	  
base-­‐pairing	  interactions	  followed	  by	  slow	  cooling	  over	  several	  days	  to	  room	  temperature	  to	  
facilitate	  annealing	  in	  a	  buffered	  solution	  with	  MgCl2	  to	  screen	  charge	  repulsions	  of	  the	  
negatively	  charged	  backbone	  phosphate	  groups.	  The	  staples	  bind	  to	  the	  scaffold	  via	  
complementary	  base	  pairing	  in	  a	  piece-­‐wise	  manner	  to	  create	  a	  seemingly	  infinite	  number	  of	  
possible	  2D	  or	  3D	  structures	  and	  a	  wide	  variety	  of	  functionalities	  that	  are	  commercial	  available.	  
In	  this	  work,	  we	  will	  exploit	  the	  geometric	  precision	  of	  DNA	  origami	  as	  well	  as	  the	  ability	  to	  add	  
chemical	  functionality	  in	  order	  to	  precisely	  control	  the	  number	  and	  spatial	  arrangement	  of	  
ligands	  specific	  for	  cell	  surface	  receptors10.	  	  	  
	  
Figure	  3:	  DNA	  Origami	  Functional	  Introduction.	  DNA	  origami	  is	  created	  by	  adding	  small	  strands	  of	  DNA	  (known	  as	  staples)	  to	  
a	  single-­‐stranded	  DNA	  molecule	  (known	  as	  scaffold.)	  Exploiting	  the	  complementary	  base	  pair	  connections,	  the	  staples	  will	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attach	  to	  the	  scaffold,	  adjoining	  particular	  areas	  to	  create	  designed	  2D	  or	  3D	  structure.	  Images	  on	  right	  are	  courtesy	  of	  
Hendrik	  Dietz,	  TUM.	  	  
	  
1.5	  Introduction	  to	  Ligand	  Presentation	  Platform	  
In	  order	  to	  better	  mimic	  a	  natural	  ligand-­‐receptor	  interaction	  during	  a	  cell-­‐cell	  interaction,	  it	  is	  
possible	  to	  employ	  a	  novel	  nanotechnological	  device	  recently	  developed	  in	  Dr.	  Carlos	  Castro’s	  
laboratory	  in	  the	  Department	  Mechanical	  and	  Aerospace	  Engineering.	  This	  device	  is	  known	  as	  a	  
Ligand	  Presentation	  Platform	  (LPP).	  An	  LPP	  is	  a	  68	  nm	  x	  25	  nm	  x	  6	  nm	  DNA	  origami	  structure11,12	  
that	  is	  hypothesized	  to	  provide	  proper	  engagement	  configuration	  and	  physical	  support	  while	  
introducing	  a	  ligand	  to	  cell	  surface	  receptors.	  This	  approach	  makes	  it	  possible	  to	  examine	  the	  
influence	  biophysical	  properties	  of	  force13,	  ligand	  quantity,	  and	  ligand	  spatial	  arrangements14	  
because	  the	  3	  x	  4	  grid	  of	  potential	  ligand-­‐binding	  biotinylated	  positions	  have	  a	  distinct	  DNA	  
sequence,	  making	  it	  possible	  to	  attach	  any	  number	  of	  biotinylated	  ligands	  at	  any	  length	  from	  
the	  platform.	  The	  biotinylated	  ligands	  can	  attach	  to	  the	  biotinylated	  nucleotide	  staple	  due	  to	  
the	  addition	  of	  streptavidin	  and	  the	  high	  affinity	  of	  streptavidin	  for	  biotin.	  Streptavidin,	  which	  
has	  four	  biotin	  binding	  sites,	  is	  used	  as	  a	  connector	  protein.	  As	  depicted	  in	  Figure	  4,	  streptavidin	  
attaches	  to	  the	  platform	  via	  a	  connection	  to	  the	  biotin	  staple	  and	  once	  streptavidin	  is	  attached	  
to	  the	  platform,	  it	  still	  presents	  biotin	  binding	  sites	  to	  solution.	  This	  makes	  it	  possible	  to	  stably	  
attach	  biotin-­‐labeled	  ligands	  (biotinylated	  antibodies)15	  to	  the	  rigid	  DNA	  structure	  in	  any	  
number	  and	  location.	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With	  this	  design,	  as	  shown	  in	  Figure	  5	  and	  Figure	  6,	  it	  is	  possible	  to	  properly	  immobilize	  
ligand(s)	  and	  study	  the	  influence	  of	  the	  ligand	  quantity,	  spatial	  arrangement,	  and	  range	  of	  
motion.	  
	  
Figure	  4:	  Ligand	  Presentation	  Platform	  functional	  introduction.	  A	  connector	  protein,	  streptavidin,	  is	  applied	  to	  attach	  a	  
biotin-­‐labeled	  staple	  to	  a	  biotin-­‐labeled	  antibody.	  Twelve	  platform	  positions	  exist	  such	  that	  an	  antibody	  can	  be	  applied	  to	  
any	  number	  and	  spatial	  configuration	  on	  the	  platform.	  	  
	  
Figure	  5:	  LPPs	  better	  mimic	  cell-­‐cell	  interactions.	  An	  antibody	  “ligand”	  is	  often	  immobilized	  when	  engaging	  with	  a	  receptor.	  
Current	  approaches	  (on	  left)	  often	  place	  ligands	  in	  solution	  and	  do	  not	  immobilize	  them.	  LPPs	  (on	  right)	  mimic	  a	  natural	  cell-­‐
cell	  reaction	  by	  immobilizing	  a	  ligand	  and	  allowing	  the	  ability	  to	  control	  ligand	  quantity	  and	  spatial	  arrangement.	  	  	  
	   9	  
	  
Figure	  6:	  Using	  LPPs	  to	  study	  cell	  signaling.	  The	  Ligand	  Presentation	  Platform	  makes	  it	  possible	  to	  study	  the	  effect	  of	  the	  (A)	  
Ligand	  Presentation	  Platform	  in	  comparison	  to	  the	  current	  experimental	  approach	  (ligands	  in	  solution),	  the	  effect	  of	  the	  (B)	  
ligand	  number,	  the	  influence	  of	  the	  (C)	  spatial	  proximity	  of	  ligands,	  and	  (D)	  the	  effect	  of	  ligand	  support	  
1.6	  Immune	  Cells:	  B	  Cells	  and	  T	  Cells	  	  
	   B	  and	  T	  lymphocytes	  are	  adaptive	  immune	  cells	  that	  work	  together	  to	  mount	  an	  
immune	  response	  and	  protect	  the	  body	  from	  foreign	  pathogens.	  B	  cells	  are	  responsible	  for	  
producing	  and	  secreting	  antibodies	  that	  specifically	  bind	  to	  a	  foreign	  antigen,	  halting	  the	  
antigens	  ability	  to	  be	  harmful	  and	  flagging	  it	  for	  destruction.	  T	  cells	  fulfill	  multiple	  critical	  roles	  
in	  an	  immune	  response.	  CD4+	  T	  helper	  cells	  identify	  antigenic	  peptide	  in	  association	  with	  major	  
histocompatibility	  complex	  II	  (MHCII)	  on	  the	  surface	  of	  antigen-­‐presenting	  cells	  and	  receive	  co-­‐
stimulatory	  signals	  to	  become	  fully	  active.	  Effector	  T	  helper	  cells	  help	  other	  immune	  cells	  such	  
as	  B	  cells	  and	  macrophages	  function	  more	  effectively	  via	  secretion	  of	  specific	  soluble	  factors	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known	  as	  cytokines.	  In	  addition,	  CD8+	  cytotoxic	  T	  cells	  recognize	  viral	  or	  tumor	  antigenic	  
peptides	  in	  association	  with	  MHCI	  on	  the	  surface	  of	  virally	  infected	  cells	  or	  cancer	  cells	  and	  
destroy	  the	  cells	  through	  perforin	  and	  granzyme	  B-­‐mediated	  targeted	  lysis.16	  When	  B	  cells	  and	  
T	  cells	  communicate	  via	  ligand-­‐receptor	  interaction,	  a	  signal	  cascade	  occurs.	  That	  is,	  as	  shown	  
in	  Figure	  7,	  receptor	  engagement	  occurs	  and	  a	  system	  full	  of	  checks	  and	  balances	  is	  activated	  
such	  that	  the	  engagement	  eventually	  leads	  to	  a	  cellular	  response.	  	  
	  
Figure	  7:	  TCR/CD3	  Signaling	  Cascade.	  This	  signaling	  cascade,	  activated	  by	  CD3	  engagement	  of	  TCR,	  is	  an	  example	  of	  how	  
ligation	  leads	  to	  a	  cascade	  of	  events	  that	  ultimately	  results	  in	  a	  cellular	  response.	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   Similar	  to	  the	  mechanism	  by	  which	  T	  cells	  become	  fully	  active,	  B	  cells	  must	  receive	  co-­‐
stimulatory	  signals	  from	  T	  cells	  to	  become	  high	  affinity	  antibody	  secreting	  plasma	  cells17.	  This	  is	  
depicted	  in	  Figure	  8.	  These	  co-­‐stimulatory	  signals	  are	  mediated	  by	  receptors	  on	  the	  B	  cell	  
surface,	  such	  as	  Cluster	  of	  Differentiation	  40	  (CD40.)	  CD40	  is	  a	  well-­‐studied	  stimulatory	  
receptor	  on	  antigen	  presenting	  immune	  cells,	  including	  B	  cells18,19.	  CD40	  signaling	  activates	  a	  
wide	  variety	  of	  B	  cell	  functions	  including	  proliferation,	  survival	  signaling,	  cytokine	  and	  
chemokine	  production,	  humoral	  immunity,	  antibody	  production,	  and	  a	  variety	  of	  other	  
functions20.	  	  
	  
Figure	  8:	  CD40	  Engagement.	  B	  cell	  CD40	  engagement	  by	  CD150	  (CD40	  Ligand)	  induces	  a	  variety	  of	  relevant	  signaling	  functions	  
including	  proliferation,	  cytokine	  and	  chemokine	  production,	  antibody	  production,	  and	  isotype	  switching.	  The	  proliferation	  
and	  pro-­‐survival	  signals	  are	  especially	  relevant	  in	  cancer	  biology.21	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These	  cellular	  responses	  are	  governed	  through	  major	  changes	  in	  gene	  expression	  
controlled	  by	  the	  activation	  of	  molecules	  known	  as	  transcription	  factors.	  Nuclear	  Factor	  Kappa	  
B	  (NF-­‐κB)	  is	  one	  transcription	  factor	  that	  is	  activated	  via	  CD40	  signaling.	  This	  transcription	  
factor	  plays	  several	  roles	  in	  the	  immune	  system,	  including	  expression	  of	  growth	  factors,	  
cytokines,	  and	  apoptosis	  inhibitors.22	  Whether	  referring	  to	  the	  classical	  or	  nonclassical	  pathway	  
(as	  describe	  in	  Figure	  9),	  dysfunction	  of	  this	  activation	  is	  thought	  to	  play	  a	  critical	  role	  in	  
proliferation,	  migration,	  and	  apoptosis	  resistance	  in	  cancer.23	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Figure	  9:	  The	  classical	  pathway	  (left)	  employs	  the	  activation	  of	  IkB	  kinase	  (IKK)	  complex	  and	  NF-­‐kB	  essential	  modulator	  
(NEMO.)	  IKK	  phosphorylates	  IkB,	  causing	  proteasomal	  degradation.	  This	  then	  undergoes	  nuclear	  translocation	  and	  activates	  
target	  genes.	  The	  nonclassical	  pathway	  (right)	  employs	  the	  activation	  of	  NF-­‐kB	  inducing	  kinase	  (NIK.)	  NIK	  phosphorylates	  IKK	  
alpha	  that	  phosphorylates	  IkB.	  	  This	  then	  undergoes	  nuclear	  translocation	  to	  and	  activates	  target	  genes.24	  
	  
Similarly	  to	  CD40	  on	  B	  cells,	  the	  T	  cell	  antigen	  receptor	  complex	  (TCR),	  expressed	  on	  T	  
cells,	  has	  been	  extensively	  studied	  and	  its	  activation	  and	  signaling	  is	  relatively	  well	  
understood25,	  making	  it	  a	  good	  model	  system	  in	  instituting	  a	  novel	  method	  to	  better	  
understand	  ligand-­‐receptor	  signaling	  in	  cell	  types	  relevant	  to	  cancer	  and	  other	  signaling-­‐related	  
disease	  phenotypes.	  Particularly	  relevant	  to	  this	  work,	  the	  importance	  of	  biophysical	  
characteristics	  of	  density	  and	  force	  on	  TCR	  activation	  have	  been	  recognized.	  The	  TCR	  is	  a	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mechanoreceptor	  activated	  by	  the	  costimulation	  of	  CD3	  and	  CD28.	  In	  addition	  to	  activation	  via	  
stimulation	  of	  CD3	  or	  costimulation	  of	  CD3	  and	  CD28,	  clustering	  of	  TCRs	  upon	  engagement	  is	  a	  
well-­‐known	  phenomenon	  that	  is	  believed	  to	  enhance	  signaling26.	  Finally,	  it	  has	  been	  established	  
that	  TCR	  is	  a	  mechanoreceptor	  that	  requires	  a	  ligand	  to	  provide	  mechanical	  force	  for	  
engagement27,28.	  	  
Upon	  T	  cell	  engagement,	  a	  signaling	  cascade	  occurs	  that	  includes	  an	  intracellular	  
calcium	  flux	  (see	  Figure	  9.)	  Calcium	  is	  a	  secondary	  messenger	  molecule	  stored	  in	  the	  
sarcoplasmic	  reticulum.	  Due	  to	  recruitment	  of	  calcium	  after	  the	  hydrolysis	  of	  
phosphatidylinositol	  4,5-­‐bisphosphate	  to	  inositol	  3,4,5-­‐triphosphate	  (IP3),	  intracellular	  calcium	  
flux	  occurs	  upon	  T	  cell	  activation	  and	  measuring	  this	  flux	  can	  be	  used	  as	  an	  indicator	  of	  receptor	  
activation29,30,31.	  In	  addition,	  relevant	  to	  mounting	  an	  effective	  immune	  response,	  activation	  
leads	  to	  Interleukin	  2	  (IL-­‐2)	  production	  and	  T	  cell	  proliferation	  and	  differentiation32,33,34.	  
Together,	  with	  their	  relevance	  to	  cancer	  signaling35,36,	  these	  well-­‐defined	  signaling	  networks	  
provide	  excellent	  models	  to	  test	  and	  develop	  a	  novel	  tool	  to	  study	  cancer-­‐relevant	  cell	  
signaling.	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Figure	  10:	  TCR	  Activation	  is	  a	  well-­‐defined	  signaling	  pathway	  that	  includes	  phosphorylation	  of	  CD3	  molecules,	  activation	  of	  
protein	  tyrosine	  kinases,	  phospholipase	  C-­‐γ1	  (PLC-­‐γ1),	  hydrolysis	  of	  phosphatidylinositol	  4,5-­‐bisphosphate	  to	  inositol	  3,4,5-­‐
triphosphate	  (IP3.)	  This	  increases	  intracellular	  calcium	  and	  IL2	  gene	  expression.	  Image	  courtesy	  of	  Abraham	  and	  Weiss.	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1.7	  Significance	  	  
	  Reduction	  in	  cancer	  death	  rates	  in	  the	  last	  two	  decades	  has	  lead	  to	  over	  1	  million	  
projected	  lives	  saved.	  Over	  the	  last	  five	  years	  with	  available	  data,	  cancer	  death	  rates	  in	  women	  
have	  decreased	  by	  1.6%	  per	  year	  while	  cancer	  death	  rates	  in	  men	  have	  decreased	  1.8%	  per	  
year.	  These	  decreases	  in	  death	  rate	  and	  these	  projected	  saved	  lives	  are	  largely	  due	  to	  more	  
effective	  diagnostics	  and	  treatments.	  However,	  in	  the	  United	  States	  alone,	  1.6	  million	  new	  
cancer	  diagnoses	  and	  over	  580	  thousand	  cancer	  deaths	  occur	  per	  year.	  Tragically,	  almost	  one	  in	  
two	  men	  one	  in	  three	  women	  are	  diagnosed	  with	  cancer	  and	  one	  in	  four	  Americans	  die	  from	  
cancer37.	  
The	  establishment	  of	  a	  more	  representative	  procedure	  to	  study	  pro-­‐growth	  and	  survival	  
cell	  signaling	  which	  may	  also	  be	  applied	  to	  death	  receptor	  signaling	  will	  allow	  cellular	  
communication	  to	  be	  examined	  on	  an	  individual	  cellular	  and	  molecular	  basis,	  providing	  
mechanistic	  information	  and	  a	  more	  thorough	  understanding	  of	  activation	  and	  signaling	  
pathways.	  Broadened	  understanding	  of	  these	  signaling	  cascades	  and	  detailed	  mechanistic	  
information	  can	  ultimately	  be	  utilized	  to	  design	  molecular	  therapeutics	  that	  target	  growth	  and	  
survival	  signaling	  networks	  in	  cancer	  cells,	  increasing	  therapeutic	  potential.	  
1.8	  Thesis	  Objective	  and	  Hypothesis	  
	   The	  objective	  of	  this	  thesis	  is	  to	  better	  understand	  cell-­‐cell	  communication	  that	  
facilitates	  growth	  and	  survival	  by	  examining	  the	  effects	  of	  ligand	  immobilization,	  spatial	  
arrangement,	  and	  biophysical	  characteristics.	  This	  is	  because	  better	  understanding	  of	  growth	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and	  survival	  signaling	  will	  lead	  to	  the	  development	  of	  effective	  targeted	  therapies	  to	  treat	  
cancer.	  	  
	   To	  do	  this,	  it	  is	  hypothesized	  that	  ligand	  spatial	  arrangement,	  linker	  length,	  and	  quantity	  
can	  be	  controlled	  on	  a	  DNA	  origami	  engineered	  nanostructure.	  Ultimately,	  a	  method	  to	  study	  
ligand-­‐receptor	  interactions	  that	  includes	  all	  of	  these	  factors	  will	  lead	  to	  increased	  	  
understanding	  of	  cell	  communication,	  thereby	  increasing	  therapeutic	  potential	  in	  cancer	  and	  
other	  diseases.	  	  
1.9	  Thesis	  Overview	  	  
	   This	  thesis	  includes	  four	  chapters:	  chapter	  1	  is	  the	  introduction	  and	  relevant	  
background,	  chapter	  2	  includes	  methodology,	  chapter	  3	  details	  results,	  and	  chapter	  4	  discusses	  
conclusions	  and	  future	  work.	  Each	  chapter	  is	  separated	  into	  subchapters	  marked	  by	  the	  chapter	  
number,	  a	  period,	  and	  the	  subchapter.	  If	  this	  is	  being	  accessed	  digitally,	  a	  click-­‐able	  table	  of	  
contents	  exists	  at	  the	  beginning	  of	  the	  document,	  on	  page	  iv.	  A	  table	  of	  figures	  exists	  on	  page	  v.	  
References	  are	  included	  on	  the	  final	  pages	  of	  the	  document.	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Chapter	  2:	  Ligand	  Presentation	  Platform	  Methodology	  	  
2.1	  Design	  
	   The	  rigid	  platform	  basis	  for	  the	  LPP	  was	  designed	  using	  caDNAno38	  such	  that	  twelve	  
binding	  sites	  exist	  in	  a	  3	  x	  4	  grid.	  Each	  binding	  site	  is	  composed	  of	  a	  biotinylated	  staple	  with	  a	  
specific	  and	  distinct	  DNA	  sequence,	  which	  determines	  its	  location	  within	  the	  structure.	  This	  site	  
specificity	  allows	  for	  inclusion	  or	  exclusion	  of	  ligand	  attachment	  sites	  at	  any	  of	  the	  twelve	  
locations.	  Furthermore,	  the	  length	  of	  the	  overhang	  on	  the	  biotinylated	  staples	  can	  be	  
individually	  controlled.	  Figure	  11	  shows	  the	  design	  of	  the	  structure.	  The	  scaffold	  is	  shown	  in	  
blue	  and	  the	  twelve	  binding	  sites	  are	  depicted	  in	  green.	  	  
	  
Figure	  11:	  caDNAno	  2	  Design.	  The	  Ligand	  Presentation	  Platform	  was	  designed	  using	  caDNAno.	  Its	  twelve	  binding	  sites	  are	  
depicted	  in	  green.	  This	  structure	  was	  originally	  designed	  by	  Emily	  Brigs,	  M.S.	  in	  the	  Nanoengineering	  Biodesign	  Lab.	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2.2	  Folding	  Reaction	  and	  Purification	  
	   The	  platform	  was	  folded	  using	  DNA	  origami	  methods	  previous	  defined	  in	  “A	  primer	  to	  
scaffolded	  DNA	  Origami39.”	  Specifically,	  a	  7560	  base	  scaffold	  derived	  from	  the	  M13mp18	  ssDNA	  
genome	  was	  placed	  in	  solution	  at	  30	  nM	  with	  1X	  Folding	  Buffer,	  20mM	  MgCl2,	  and	  the	  
oligonucleotide	  staple	  strands	  designed	  in	  caDNAno	  and	  ordered	  from	  a	  commercial	  vendor	  
(Eurofins	  Genomics),	  so	  that	  each	  staple	  was	  at	  excess	  (200	  nM)	  compared	  to	  the	  scaffold.	  	  A	  
6.5	  day	  thermal	  ramp	  of	  rapid	  heating	  to	  65	  degrees	  C	  and	  slow	  cooling	  was	  applied	  to	  facilitate	  
self	  assembly.	  Several	  versions	  of	  the	  LPP	  were	  folded	  where	  biotinylated	  oligonucleotide	  
staples	  included	  in	  the	  folding	  reactions	  varied	  based	  on	  desired	  linker	  length	  and	  desired	  
number	  of	  ligands	  on	  the	  platform.	  Figures	  12	  and	  13	  display	  the	  varied	  linker	  lengths,	  
quantities,	  and	  spatial	  arrangements.	  	  
	  
Figure	  12:	  Linker	  length	  can	  be	  controlled	  as	  desired,	  for	  example	  linker	  length	  of	  5	  base-­‐pairs	  (5T),	  15	  base-­‐pairs	  (15T),	  and	  
30	  base-­‐pairs	  (30T.)	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Figure	  13:	  Number	  of	  attached	  ligands	  and	  locations	  of	  attachment	  can	  be	  controlled	  as	  desired.	  For	  example	  LPP1,	  LPP2	  
(close),	  LPP2	  (distant),	  LPP4	  (close),	  LPP4	  (distant),	  LPP12,	  or	  any	  other	  combination	  of	  the	  12	  ligand	  locations.	  	  
	   	  
After	  the	  self-­‐assembly	  reaction,	  reactant	  products	  were	  subjected	  to	  purification	  to	  
remove	  excess	  staple	  strands.	  The	  folding	  reaction	  was	  added	  in	  equal	  volume	  to	  15%	  
polyethylene	  glycol	  (PEG)	  8000	  and	  this	  mixture	  was	  centrifuged	  at	  16000	  g	  for	  30	  minutes	  at	  4	  
degrees	  C.	  The	  supernatant	  containing	  the	  excess	  ssDNA	  oligos	  was	  removed	  and	  discarded	  
while	  the	  pellet	  containing	  the	  folded	  DNA	  origami	  structures	  was	  resuspended	  in	  1X	  FOB	  and	  
18mM	  MgCl2.	  To	  confirm	  well-­‐folded	  nanostructures,	  folding	  reaction	  products	  were	  also	  
subjected	  to	  gel	  electrophoresis,	  purification,	  and	  transmission	  electron	  microscopy	  described	  
below.	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  2.3	  Functionalization	  with	  Streptavidin	  and	  Antibody	  
	   UV	  absorption	  was	  used	  to	  measure	  the	  concentration	  of	  the	  DNA	  origami	  
nanostructures.	  Streptavidin	  was	  added	  in	  40-­‐fold	  molar	  excess	  and	  incubated	  for	  1	  hour	  at	  
room	  temperature.	  Biotinylated	  antibodies	  were	  added	  at	  10-­‐fold	  molar	  excess	  and	  incubated	  
overnight	  at	  4	  degrees	  C.	  	  
2.4	  Verification	  via	  Gel	  Electrophoresis	  
	   To	  verify	  properly	  folded	  structures,	  gel	  electrophoresis	  was	  used.	  The	  products	  of	  the	  
folding	  reaction	  were	  run	  through	  a	  2%	  agarose	  gel	  in	  the	  presence	  of	  0.5X	  TBE	  and	  11mM	  
MgCl2.	  Gels	  were	  run	  at	  70V	  for	  1-­‐4	  hours	  to	  allow	  time	  for	  band	  separation.	  The	  resulting	  gel	  
was	  imaged	  and	  leading	  bands	  were	  excised.	  	  
2.5	  Verification	  via	  Transmission	  Electron	  Microscopy	  	  
	   To	  further	  verify,	  unfunctionalized	  structures,	  structures	  with	  streptavidin,	  and	  
structures	  with	  streptavidin	  and	  antibody	  were	  imaged	  via	  transmission	  electron	  microscopy	  
(TEM.)	  The	  products	  of	  the	  gel	  electrophoresis	  were	  placed	  on	  copper	  mesh	  grids	  and	  
negatively	  stained	  with	  uranyl	  formate	  as	  previously	  described	  in	  Castro,	  Nat.	  Method,	  201140.	  
The	  nanostructures	  were	  imaged	  at	  an	  electron	  acceleration	  voltage	  of	  80kV	  on	  a	  Tecnai	  G2	  
BioTWIN	  TEM.	  	  
2.6	  Fluorescent	  Microscopy:	  B	  cells	  over	  20	  hours	  
	   To	  evaluate	  functionalized	  nanostructure-­‐anti-­‐CD40	  induced	  NF-­‐κB	  response,	  single	  cell	  
epifluorescence	  imaging	  was	  employed	  on	  CH12.LX	  B	  cells41.	  Nucleofection	  (Amaxa	  program	  0-­‐
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003)	  with	  2.5-­‐5	  μg	  of	  Cignal	  GFP-­‐NF-­‐κB	  reporter	  construct	  (SA	  Biosciences)	  was	  used	  to	  
transfect	  1	  million	  CH12.LX	  B	  cells.	  After	  transfection,	  cells	  were	  incubated	  overnight	  at	  37	  
degrees	  C	  and	  5%	  CO2	  in	  complete	  medium	  (RPMI	  1640	  (CellGrow)	  media	  containing	  10%	  FBS	  
(Atlas	  Biologicals),	  20mM	  HEPES	  (Gibco),	  100	  U/ml	  penicillin	  (Gibco),	  100	  µg/ml	  streptomycin	  
(Gibco)	  and	  2mM	  L-­‐glutamine	  (Gibco),	  and	  50µM	  2-­‐ME	  (Sigma	  Aldrich))	  and	  then	  resuspended	  
in	  clear	  RPMI	  1640	  (Gibco),	  0.5%	  FBS,	  and	  2%	  penicillin/streptomycin/L-­‐Glutamine.	  Cells	  were	  
plated	  in	  live	  cell	  imaging	  wells	  (Thermo	  Scientific)	  and	  functionalized	  LPPs	  were	  added	  at	  600	  
pM.	  The	  sample	  was	  incubated	  in	  the	  presence	  of	  7-­‐AAD	  (1:100)	  in	  a	  stage-­‐top	  incubator	  at	  37	  
degrees	  C	  and	  5%	  CO2	  throughout	  the	  20	  hours	  of	  imaging	  on	  a	  Nikon	  Eclipse	  Ti2.	  The	  level	  of	  
NF-­‐κB	  cellular	  response	  was	  quantified	  via	  epiflorescence	  imaging	  emission	  of	  the	  GFP	  reporter	  
at	  488	  nm	  excitation.	  Cell	  viability	  was	  determined	  via	  epifluorescence	  imaging	  emission	  of	  the	  
7-­‐AAD	  at	  561	  nm	  excitation.	  	  
2.7	  Fluorescent	  Microscopy:	  T	  cells	  over	  5	  minutes	  
To	  begin	  evaluating	  functionalized	  nanostructure-­‐anti-­‐CD3	  induced	  calcium	  response,	  
single	  cell	  epifluorescence	  imaging	  was	  employed.	  Jurkat	  T	  cells	  (2	  million/mL)	  cultured	  in	  
altered	  complete	  RPMI	  (RPMI	  1640	  (CellGrow)	  media	  containing	  10%	  FBS	  (Atlas	  Biologicals),	  
100	  U/ml	  penicillin	  (Gibco),	  100	  µg/ml	  streptomycin	  (Gibco)	  and	  2mM	  L-­‐glutamine	  (Gibco))	  
were	  dyed	  at	  1	  mM	  Fluo-­‐4	  AM	  (Life	  Technologies)	  and	  incubated	  in	  HBSS	  for	  30	  minutes	  at	  37	  
degrees	  C	  and	  5%	  CO2.	  Cells	  were	  plated	  in	  live	  cell	  imaging	  wells	  (Thermo	  Scientific)	  and	  
incubated	  for	  an	  additional	  45	  minutes	  at	  the	  conditions	  described	  above.	  During	  imaging,	  the	  
sample	  was	  incubated	  in	  a	  stage-­‐top	  incubator	  at	  37	  degrees	  C	  and	  5%	  CO2	  on	  a	  Nikon	  Eclipse	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Ti2.	  After	  one	  minute	  of	  imaging,	  the	  stimulus	  was	  added.	  Stumuli	  included	  soluble	  anti-­‐CD3	  
(OKT3)-­‐biotin	  (eBioscience)	  at	  10	  µg/mL	  and	  a	  buffer	  only	  negative	  control.	  The	  level	  of	  
intracellular	  calcium	  response	  was	  quantified	  via	  epiflorescence	  imaging	  with	  488	  nm	  
excitation.	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Chapter	  3:	  Results	  	  
3.1	  Gel	  Electrophoresis	  
	   Figure	  14	  depicts	  typical	  results	  from	  gel	  electrophoresis	  purification	  of	  LPP	  
nanostructures.	  Several	  samples	  were	  run	  on	  the	  gel	  including	  a	  1kb	  reference	  ladder	  (New	  
England	  Biolabs)	  on	  the	  far	  left	  and	  far	  right	  wells,	  the	  7560	  base	  scaffold	  in	  the	  second	  lane,	  
resulting	  in	  one	  tight	  band,	  and	  the	  folded	  structure	  bands	  in	  lanes	  3-­‐14.	  Because	  smaller	  DNA	  
objects	  pass	  through	  the	  agarose	  gel	  more	  quickly,	  the	  gel	  results	  in	  separation	  of	  structures	  by	  
size.	  The	  lanes	  with	  the	  folded	  structures	  included	  a	  large	  bright	  smear	  corresponding	  to	  the	  
excess	  staples	  that	  ran	  the	  farthest,	  a	  narrow	  bright	  band	  corresponding	  to	  the	  well	  folded	  
structure,	  and	  a	  faint	  smear	  between	  the	  well	  and	  structure	  band	  corresponding	  to	  misfolded	  
or	  aggregated	  structures.	  Well-­‐folded	  structures	  form	  a	  tight	  band	  that	  runs	  slightly	  faster	  than	  
the	  reference	  scaffold	  because	  they	  are	  more	  compact	  than	  the	  unfolded	  scaffold.	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Figure	  14:	  Gel	  Electrophoresis.	  LPP1-­‐5T,	  LPP1-­‐15T,	  and	  LPP1-­‐30T	  underwent	  gel	  electrophoresis	  with	  ladder	  controls	  and	  a	  
7560	  base-­‐pair	  reference	  control.	  
3.2	  Transmission	  Electron	  Microscopy	  
	   To	  further	  verify	  well-­‐folded	  structures,	  structures	  were	  imaged	  via	  transmission	  
electron	  microscopy	  (TEM.)	  As	  shown	  in	  Figure	  15	  and	  Figure	  16,	  transmission	  electron	  
microscopy	  resulted	  in	  visualization	  of	  LPPs	  with	  proper	  streptavidin	  and	  antibody	  attachment	  
number	  and	  location,	  as	  shown	  in	  proper	  quantity	  and	  location	  on	  LPP1,	  LPP2,	  and	  LPP4.	  In	  
addition,	  TEM	  can	  verify	  antibody	  attachment	  to	  streptavidin,	  as	  shown	  in	  Figure	  16.	  This	  figure	  
depicts	  LPP1	  with	  streptavidin	  and	  with	  streptavidin/antibody	  attachment.	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Figure	  15:	  TEM	  Streptavidin	  Attachment.	  Cartoon	  image	  (left)	  and	  TEM	  image	  (right)	  showed	  that	  streptavidin	  (marked	  with	  
red	  arrows)	  attaches	  in	  the	  number	  and	  location	  that	  is	  expected.	  
	  
	  
Figure	  16:	  TEM	  streptavidin	  and	  antibody	  attachment.	  Cartoon	  image	  (left),	  TEM	  image	  of	  streptavidin	  only	  added	  (middle),	  
and	  TEM	  image	  of	  streptavidin	  and	  antibody	  (right)	  showed	  that	  antibody	  attaches	  as	  expected.	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3.3	  Fluorescent	  Microscopy:	  B	  cells	  over	  20	  hours	  
	   To	  analyze	  the	  functionalization	  of	  the	  structures,	  fluorescent	  microscopy	  was	  
completed.	  This	  examination	  resulted	  in	  observation	  of	  an	  increased	  response	  in	  reporter	  
fluorescence,	  indicating	  increased	  production	  of	  GFP	  due	  to	  NF-­‐κB	  activation	  in	  response	  to	  
CD40L	  functionalized	  nanostructures.	  Experiments	  were	  controlled	  with	  a	  none	  negative	  
control,	  a	  platform	  with	  streptavidin	  only,	  and	  a	  platform	  with	  an	  isotype	  control	  antibody	  
attached.	  	  
As	  shown	  in	  Figures	  17-­‐21,	  a	  ~4-­‐fold	  change	  existed	  compared	  to	  controls	  after	  20	  
hours.	  In	  Figure	  17,	  a	  qualitative	  change	  is	  clearly	  observable	  between	  LPP2	  with	  anti-­‐CD40	  
relative	  to	  controls	  at	  20	  hours.	  In	  Figure	  18,	  a	  ~4-­‐fold	  quantitative	  change	  induced	  by	  LPP2	  
anti-­‐CD40	  is	  shown	  after	  20	  hours	  relative	  to	  the	  controls.	  Figure	  19	  displays	  a	  ~3-­‐fold	  change	  
induced	  by	  LPP11	  anti-­‐CD40	  compared	  to	  the	  controls.	  	  Finally,	  in	  Figure	  20,	  a	  ~2	  fold	  change	  
induced	  by	  LPP12	  anti-­‐CD40	  is	  shown	  at	  20	  hours	  relative	  to	  the	  controls.	  Therefore,	  a	  
downward	  trend	  existed	  in	  that	  LPPs	  with	  more	  ligands	  produce	  less	  response	  than	  platforms	  
with	  fewer	  ligands.	  	  
In	  addition,	  as	  shown	  in	  Figure	  22,	  the	  response	  was	  concentration	  dependent.	  While	  
the	  concentration	  of	  the	  structures	  was	  unknown,	  when	  the	  structures	  were	  added	  at	  a	  higher	  
concentration	  (1:10	  indicates	  the	  volume	  of	  structures	  added	  to	  volume	  of	  cell	  solution)	  and	  
subsequent	  ten-­‐fold	  serial	  dilutions	  (1:100	  and	  1:1000)	  were	  completed,	  a	  higher	  magnitude	  
response	  was	  observed	  when	  LPP	  structures	  were	  added	  at	  a	  higher	  concentration.	  Figure	  23	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shows	  a	  decreasing	  response	  with	  increasing	  concentration	  of	  inhibitor,	  Bay-­‐11-­‐7082,	  
confirming	  that	  the	  response	  is	  capable	  of	  being	  inhibited	  by	  an	  NF-­‐κB	  cascade	  blocker.	  	  
	  
	  
Figure	  17:	  Qualitative	  functional	  response.	  A	  qualitative	  difference	  is	  exhibited	  between	  functionalized	  structures	  (on	  right)	  
and	  controls	  (all	  others)	  after	  20	  hours.	  The	  relative	  level	  of	  fluorescence	  corresponds	  to	  GFP	  production	  via	  CD40L	  
activation.	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Figure	  18:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  B	  cells.	  Functionalized	  LPP2-­‐5T	  (right)	  with	  controls	  (no	  
stimulus,	  LPP	  with	  streptavidin,	  and	  LPP	  with	  isotype	  control	  antibody.)	  The	  level	  of	  GFP-­‐NF-­‐κB	  was	  measured	  on	  individual	  
cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  condition.	  
Images	  and	  data	  represent	  two	  experiments.	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Figure	  19:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  B	  cells.	  Functionalized	  LPP11-­‐5T	  (right)	  with	  controls	  
(no	  stimulus,	  LPP	  with	  streptavidin,	  and	  LPP	  with	  isotype	  control	  antibody.)	  The	  level	  of	  GFP-­‐NF-­‐κB	  was	  measured	  on	  
individual	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  
condition.	  Images	  and	  data	  represent	  two	  experiments.	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Figure	  20:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  B	  cells.	  Functionalized	  LPP12-­‐5T	  (right)	  with	  controls	  
(no	  stimulus,	  LPP	  with	  streptavidin,	  and	  LPP	  with	  isotype	  control	  antibody.)	  The	  level	  of	  GFP-­‐NF-­‐κB	  was	  measured	  on	  
individual	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	  the	  intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  
condition.	  Images	  and	  data	  represent	  two	  experiments.	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Figure	  21:	  Fluorescent	  microcopy	  to	  measure	  concentration	  dependence	  in	  B	  cells.	  Anti-­‐CD40	  functionalized	  LPP1-­‐5T	  showed	  
a	  concentration	  dependent	  change	  in	  signal	  induction.	  The	  level	  of	  GFP-­‐NF-­‐κB	  was	  measured	  on	  at	  least	  40	  cells	  per	  
condition	  and	  the	  data	  is	  presented	  as	  the	  intensity	  mean	  Fold	  Change	  +	  SEM	  relative	  to	  0	  hours	  for	  each	  condition.	  Images	  
and	  data	  represent	  one	  experiment.	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Figure	  22:	  Fluorescent	  microscopy	  to	  measure	  inhibition	  of	  signal	  in	  B	  cells.	  anti-­‐CD40	  functionalized	  LPP2-­‐5T	  showed	  an	  
ability	  to	  be	  inhibited	  by	  Bay-­‐11-­‐7082.	  
3.5	  Fluorescent	  Microscopy:	  T	  cells	  over	  5	  minutes	  
	   To	  further	  support	  that	  this	  nanostructure	  is	  an	  effective	  way	  to	  study	  cell	  
communication,	  the	  process	  is	  shown	  on	  an	  additional	  cell	  type,	  receptor-­‐ligand	  interaction,	  
and	  subsequent	  cellular	  response.	  Fluorescent	  microscopy	  showed	  an	  increased	  response	  in	  
488	  fluorescence,	  indicating	  influx	  of	  intracellular	  calcium	  after	  the	  addition	  of	  soluble	  anti-­‐CD3.	  
This	  experiment	  was	  controlled	  with	  a	  none	  negative	  control.	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Figure	  23:	  Fluorescent	  microscopy	  to	  measure	  functional	  response	  in	  T	  cells.	  Soluble	  anti-­‐CD3-­‐biotin	  was	  added	  to	  T	  cells	  at	  
60	  seconds.	  The	  level	  of	  intracellular	  calcium	  was	  measured	  on	  at	  least	  150	  cells	  per	  condition	  and	  the	  data	  is	  presented	  as	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Chapter	  4:	  Conclusions	  and	  Future	  Work	  	  	  	  
Cell	  to	  cell	  communication	  is	  relevant	  in	  the	  development	  of	  well-­‐targeted,	  effective	  
cancer	  therapeutics	  against	  specific	  pro-­‐growth	  and	  survival	  intracellular	  signaling	  pathways.	  
Current	  methods	  to	  study	  cell-­‐cell	  communication	  fail	  to	  ensure	  correct	  ligand	  immobilization	  
and	  lack	  the	  ability	  to	  study	  the	  influence	  of	  ligand	  spatial	  arrangement	  and	  range	  of	  motion.	  	  In	  
order	  to	  establish	  a	  ligand-­‐receptor	  examination	  method	  that	  more	  closely	  mimics	  natural	  cell-­‐
cell	  communication,	  well-­‐defined	  signaling	  pathways	  should	  be	  examined.	  Two	  well-­‐defined	  
pathways,	  CD40	  induction	  of	  NF-­‐κB	  in	  B	  cells	  and	  calcium	  influx	  via	  CD3	  engagement	  in	  T	  cells,	  
are	  such	  examples	  and	  are	  in	  the	  process	  of	  being	  examined	  using	  a	  novel	  nanoengineering	  
technique.	  	  
This	  technique	  synthesizes	  a	  nanoplatform	  using	  a	  method	  called	  scaffolded	  DNA.	  This	  
platform	  correctly	  immobilizes	  a	  ligand	  and	  makes	  it	  possible	  to	  study	  the	  influence	  of	  ligand	  
spatial	  arrangement	  and	  local	  flexibility	  of	  the	  ligand.	  The	  LPP	  nanostructure	  has	  shown	  that	  it	  
can	  be	  folded	  and	  functionalized	  with	  streptavidin	  and	  antibody	  in	  the	  quantity,	  spatial	  
arrangement,	  and	  range	  of	  motion	  that	  is	  desired.	  In	  B	  cells,	  it	  has	  shown	  to	  be	  functional	  and	  
induce	  a	  functional	  response	  at	  a	  ~4-­‐fold	  magnitude	  to	  relevant	  controls.	  While	  the	  T	  cell	  TCR	  
data	  is	  preliminary	  and	  LPP	  nanostructures	  have	  not	  yet	  been	  tested	  in	  this	  system,	  the	  soluble	  
ligand	  response	  is	  comparable	  in	  time	  scale	  and	  magnitude	  to	  established	  published	  responses	  
in	  similar	  systems42,43.	  
Future	  experiments	  will	  be	  designed	  to	  assess	  the	  importance	  of	  ligand	  quantity	  and	  
range	  of	  motion.	  On	  both	  T	  cell	  and	  B	  cell	  systems,	  relevance	  of	  ligand	  quantity	  and	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concentration	  will	  be	  examined	  by	  varying	  both	  concentration	  of	  LPP	  structures	  and	  ligand	  
quantity	  on	  the	  LPP	  structure	  from	  one	  ligand	  (LPP1)	  to	  twelve	  ligands	  (LPP12.)	  Examination	  of	  
ligand	  range	  of	  motion	  should	  also	  be	  tested	  in	  the	  T	  cell	  and	  B	  cell	  system	  by	  comparing	  LPP1-­‐
5T	  (ligand	  attached	  by	  5	  base	  linker)	  to	  LPP1-­‐15T	  (ligand	  attached	  by	  15	  base	  linker)	  	  and	  LPP1-­‐
30T	  (ligand	  attached	  by	  30	  base	  linker).	  	  	  
To	  ensure	  that	  the	  functional	  response	  is	  caused	  by	  the	  signaling	  cascades	  expected,	  
inhibitor	  tests	  should	  be	  completed	  in	  both	  systems.	  	  In	  addition	  to	  the	  immortalized	  cell	  lines	  
used,	  primary	  B	  cells	  and	  T	  cells	  should	  be	  tested	  in	  order	  to	  ensure	  physiological	  relevance.	  
Finally,	  to	  further	  confirm	  the	  results	  found	  on	  a	  single	  cell	  level	  using	  fluorescence	  imaging,	  
flow	  cytometry	  and	  flourometer	  analysis	  should	  be	  employed	  to	  visualize	  the	  response	  on	  a	  
population	  level.	  	  
Ultimately,	  if	  proteins	  or	  other	  molecules	  can	  be	  attached	  to	  this	  nanostructure	  to	  cause	  
a	  cellular	  functional	  response,	  then	  these	  nanostructures	  can	  be	  used	  both	  to	  examine	  and	  
understand	  signaling	  cascades	  as	  well	  as	  to	  deliver	  therapeutic	  messages.	  For	  example,	  these	  
structures	  can	  be	  used	  to	  examine	  a	  poorly	  understood	  ligand-­‐receptor	  interaction	  that	  may	  be	  
relevant	  in	  cancer	  pathology.	  Furthermore,	  if	  the	  platform	  can	  deliver	  a	  protein	  that	  leads	  to	  




	   37	  
	  
Bibliography	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Cancer	  Prevention	  and	  Control	  by	  Centers	  for	  Disease	  Control	  and	  Prevention.	  Retrieved	  June	  
4,	  2014	  from	  http://www.cdc.gov/cancer/dcpc/resources/features/worldcancerday/	  
2	  Institute,	  N.C.	  (2013,	  June	  14).	  Surveillance	  Epidemiology	  and	  End	  Results.	  Retrieved	  
September	  18,	  2013,	  from	  http://seer.cancer.gov/csr/1975_2010/sections.html	  
3	  Sawyers,	  Charles.	  “Targeted	  Cancer	  Therapy.”	  Nature	  432.7015	  (2004):	  294-­‐97.	  
4	  Scitable:	  by	  Nature	  Education.	  Cell	  Signaling.	  Retrieved	  September	  18,	  2013	  from	  
www.nature.com/scitable/topicpage/cell-­‐signaling-­‐14047077	  
5	  Pray,	  L.	  “Discovery	  of	  DNA	  Structure	  and	  Function:	  Watson	  and	  Crick.”	  Nature	  Education	  
1.1:100	  (2008).	  
6	  Pray,	  L.	  “Discovery	  of	  DNA	  Structure	  and	  Function:	  Watson	  and	  Crick.”	  Nature	  Education	  
1.1:100	  (2008).	  
7	  Seeman,	  N.	  “Nucleic	  Acid	  Junctions	  and	  Lattices.”	  Journal	  of	  Theoretical	  Biology	  99	  (1982):237-­‐
247.	  
8	  Chen,	  J.,	  Seeman,	  N.	  “Synthesis	  from	  DNA	  of	  a	  molecule	  with	  the	  connectivity	  of	  a	  cube.”	  
Nature.	  350	  (1991):631-­‐633.	  
9	  Linko,	  V.,	  Dietz,	  H.	  “The	  enabled	  state	  of	  DNA	  nanotechnology.”	  Current	  Opinion	  in	  
Biotechnology.	  24	  (2013):555-­‐561.	  
10	  Rothemund,	  Paul.	  “Folding	  DNA	  to	  create	  nanoscale	  shapes	  and	  patterns.”	  Nature	  	  440	  
(2006):297-­‐302.	  
11	  Rothemund,	  Paul.	  “Folding	  DNA	  to	  create	  nanoscale	  shapes	  and	  patterns.”	  Nature	  440	  
(2006):297-­‐302.	  
12	  Castro,	  C.,	  Kilchherr,	  F.,	  Kim,	  D,	  Shiao,	  E.,	  Wauer,	  T.,	  Wortmann,	  P.,	  Bathe,	  M.,	  Dietz,	  H.	  “A	  
primer	  to	  scaffolded	  DNA	  origami.”	  Nature	  Methods.	  8(2011):221-­‐229.	  
13	  Kim,	  S.T.,	  Takeuchi,	  K.,	  Sun,	  Z.Y.J.,	  Touma,	  M.,	  Castro,	  C.E.,	  Fahmy,	  A.,	  Lang,	  M.J.,	  Wagner,	  G.,	  
Reinherz,	  E.L.	  “The	  αβ	  T	  Cell	  Receptor	  Is	  an	  Anisotropic	  Mechanosensor.”	  Journal	  of	  Biological	  
Chemistry	  284.45	  (2009):	  31028-­‐37.	  
14	  Dykstra,	  M.,	  Cherukuri,	  A.,	  Sohn,	  H.W.,	  Tzeng,	  S.J.,	  Pierce,	  S.	  “Location	  is	  Everything:	  Lipid	  
Rafts	  and	  Immune	  Cell	  Signaling.”	  Annual	  Review	  on	  Immunology	  21	  (2003):457-­‐81.	  
15	  Homberg,	  A.,	  Blomstergren,	  A.,	  Nord,	  O.,	  Lukacs,	  M.,	  Lundeberg,	  J.,	  Uhlen,	  M.	  “The	  biotin-­‐
streptavidin	  interaction	  can	  be	  reversibly	  broken	  using	  water	  at	  elevated	  temperatures.”	  
Electrophoresis	  26.3	  (2005):	  501-­‐10.	  
16	  Alberts.	  Molecular	  and	  Cell	  Biology.	  Edition	  5	  (2007.)	  Chapter	  25:	  1539-­‐1541.	  
17	  Alberts.	  Molecular	  and	  Cell	  Biology.	  Edition	  5	  (2007.)	  Chapter	  25:	  1539-­‐1541.	  
18	  Bishop,	  G.,	  Hostager,	  B.	  “The	  CD40-­‐CD154	  interaction	  in	  B	  cell-­‐T	  cell	  liaisons.”	  Cytokine	  and	  
Growth	  Factor	  Reviews.	  14,	  3-­‐4	  (2003):297-­‐309.	  
19	  Bergwelt-­‐Baildon,	  M.,	  Maecker,	  B.,	  Schultze,	  J.,	  Gribben,	  J.	  “CD40	  activation:	  potential	  for	  
specific	  immunotherapy	  in	  B-­‐CLL.	  15(2004):853-­‐857.	  	  
20	  Graham,	  J.,	  Arcipowski,	  K.,	  Bishop,	  G.	  “Differential	  B-­‐lymphocyte	  regulation	  by	  CD40	  and	  its	  
viral	  mimic,	  latent	  membrane	  protein	  1.”	  Immunological	  Reviews	  237.1	  (2010):	  226-­‐248.	  
	   38	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
21	  Graham,	  J.,	  Arcipowski,	  K.,	  Bishop,	  G.	  “Differential	  B-­‐lymphocyte	  regulation	  by	  CD40	  and	  its	  
viral	  mimic,	  latent	  membrane	  protein	  1.”	  Immunological	  Reviews	  237.1	  (2010):	  226-­‐248.	  
22	  Memet,	  S.	  “NFkB	  functions	  in	  the	  nervous	  system:	  from	  development	  to	  disease.”	  
Biochemical	  Pharmacology	  72	  (2006):	  1180-­‐1195.	  	  
23	  Dolcet,	  X.,	  Llobet,	  D.,	  Pallares,	  J.,	  Matias-­‐Guiu,	  X.	  “NF-­‐kB	  in	  development	  and	  progression	  of	  
human	  cancer.”	  Virchows	  Archiv	  446.5	  (2005):	  475-­‐82.	  
24	  Hooper,	  C.	  “Overview	  of	  NFkB	  signaling.”	  Abcam.	  Retrieved	  June	  4,	  2014	  from	  
http://www.abcam.com/?pageconfig=resource&rid=11255&pid=10629	  
25	  Smith-­‐Garvin,	  J.E.,	  Koretzky,	  G.A.,	  Jordan,	  M.S.	  “T	  Cell	  Activation.”	  Annual	  Review	  on	  
Immunology	  27	  (2009):	  591-­‐619.	  
26	  Dykstra,	  M.,	  Cherukuri,	  A.,	  Sohn,	  H.W.,	  Tzeng,	  S.J.,	  Pierce,	  S.	  “Location	  is	  Everything:	  Lipid	  
Rafts	  and	  Immune	  Cell	  Signaling.”	  Annual	  Review	  on	  Immunology	  21	  (2003):457-­‐81.	  
27	  Natkanski,	  E.,	  Lee,	  W.,	  Mistry,	  B.,	  Casal,	  A.,	  Molloy,	  J.,	  Tolar,	  P.	  “B	  Cells	  Use	  Mechanical	  Energy	  
to	  Discriminate	  Antigen	  Affinities.”	  Science	  340.5140	  (2013):1587-­‐90.	  
28	  Kim,	  S.T.,	  Takeuchi,	  K.,	  Sun,	  Z.Y.J.,	  Touma,	  M.,	  Castro,	  C.E.,	  Fahmy,	  A.,	  Lang,	  M.J.,	  Wagner,	  G.,	  
Reinherz,	  E.L.	  “The	  αβ	  T	  Cell	  Receptor	  Is	  an	  Anisotropic	  Mechanosensor.”	  Journal	  of	  Biological	  
Chemistry	  284.45	  (2009):	  31028-­‐37.	  
29	  Smith-­‐Garvin,	  J.E.,	  Koretzky,	  G.A.,	  Jordan,	  M.S.	  “T	  Cell	  Activation.”	  Annual	  Review	  on	  
Immunology	  27	  (2009):	  591-­‐619.	  
30	  Oh-­‐hora,	  M.,	  Rao,	  A.	  “Calcium	  signaling	  in	  lymphocytes.”	  Annual	  Review	  of	  Immmunology.	  20	  
(2008):250-­‐8	  
31	  Smith-­‐Garvin,	  J.E.,	  Koretzky,	  G.A.,	  Jordan,	  M.S.	  “T	  Cell	  Activation.”	  Annual	  Review	  on	  
Immunology	  27	  (2009):	  591-­‐619.	  
32	  Alberts.	  Molecular	  and	  Cell	  Biology.	  Edition	  5	  (2007.)	  Chapter	  25:	  1540-­‐1551.	  
33	  Smith-­‐Garvin,	  J.E.,	  Koretzky,	  G.A.,	  Jordan,	  M.S.	  “T	  Cell	  Activation.”	  Annual	  Review	  on	  
Immunology	  27	  (2009):	  591-­‐619.	  
34	  Kim,	  S.T.,	  Takeuchi,	  K.,	  Sun,	  Z.Y.J.,	  Touma,	  M.,	  Castro,	  C.E.,	  Fahmy,	  A.,	  Lang,	  M.J.,	  Wagner,	  G.,	  
Reinherz,	  E.L.	  “The	  αβ	  T	  Cell	  Receptor	  Is	  an	  Anisotropic	  Mechanosensor.”	  Journal	  of	  Biological	  
Chemistry	  284.45	  (2009):	  31028-­‐37.	  
35	  Bergwelt-­‐Baildon,	  M.,	  Maecker,	  B.,	  Schultze,	  J.,	  Gribben,	  J.	  “CD40	  activation:	  potential	  for	  
specific	  immunotherapy	  in	  B-­‐CLL.	  15(2004):853-­‐857.	  	  
36	  Warner,	  K.,	  Weit,	  N.,	  Crispatzu,	  G.,	  Admirand,	  J.,	  Jones,	  D.	  “T-­‐Cell	  Receptor	  Signaling	  in	  
Peripheral	  T-­‐Cell	  Lymphoma	  –	  A	  Review	  of	  Patterns	  of	  Alterations	  in	  a	  Central	  Growth	  
Regulatory	  Pathway.”	  Current	  Hematologic	  Malignancy	  Report.	  163,	  10	  (2013):163-­‐172.	  
37	  Siegel,	  R.,	  Naishadham,	  D.,	  Jemal,	  A.	  “Cancer	  Statistics,	  2012.”	  Cancer	  Journal	  for	  Clinicians	  62	  
(2012):	  10-­‐29.	  
38	  Douglas,	  S.,	  Marblestone,	  A.,	  Teerapittayanon,	  S.,	  Vazquez,	  A.,	  Church,	  G.,	  Shih,	  W.	  “Rapid	  
prototyping	  of	  3D	  DNA-­‐origami	  shapes	  with	  caDNAno.”	  Nucleic	  Acids	  Research.	  10.1093	  
(2009):1-­‐6.	  
39	  Castro,	  C.,	  Kilchherr,	  F.,	  Kim,	  D,	  Shiao,	  E.,	  Wauer,	  T.,	  Wortmann,	  P.,	  Bathe,	  M.,	  Dietz,	  H.	  “A	  
primer	  to	  scaffolded	  DNA	  origami.”	  Nature	  Methods.	  8(2011):221-­‐229.	  
40	  Castro,	  C.,	  Kilchherr,	  F.,	  Kim,	  D,	  Shiao,	  E.,	  Wauer,	  T.,	  Wortmann,	  P.,	  Bathe,	  M.,	  Dietz,	  H.	  “A	  
primer	  to	  scaffolded	  DNA	  origami.”	  Nature	  Methods.	  8(2011):221-­‐229.	  
	   39	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
41	  Bishop,	  G.A.,	  Haughton,	  G.	  “Induced	  differentiation	  of	  a	  transformed	  clone	  of	  Ly-­‐1+	  B	  cells	  by	  
clonal	  T	  cells	  and	  antigen.”	  Proc.	  Natl.	  Acad.	  Sci.	  83(1986):7410-­‐7414.	  
42	  Xavier,	  R.,	  Brennan,	  T.,	  Li,	  Q.,	  McCormack,	  C.,	  Seed,	  B.	  “Membrane	  Compartmentation	  Is	  
Required	  for	  Efficient	  T	  Cell	  Activation.”	  Immunity.	  8,	  6	  (1998):723-­‐732.	  
43	  Bailey,	  S.,	  Macardle,	  P.	  “A	  flow	  cytometric	  comparison	  of	  Indo-­‐1	  to	  fluo-­‐3	  and	  Fura	  Red	  
excited	  with	  low	  power	  lasers	  for	  detecting	  Ca2+	  flux.”	  Journal	  of	  Immunological	  Methods.	  
311(2006)220-­‐225.	  
